We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CTMX market cap is 117.16M. The company's latest EPS is USD -0.0084 and P/E is -205.95.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 16.92M | 946k | 23.5M | 24.72M | 26.38M |
| Operating Income | -23.94M | -28.69M | -5.65M | -3.35M | 3.12M |
| Net Income | -23.3M | -27.95M | -3.31M | -1.09M | 2.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 57.49M | 100.36M | 69.57M | 53.16M | 101.21M |
| Operating Income | -110.9M | -48.61M | -83.78M | -101.34M | -6.48M |
| Net Income | -102.24M | -32.89M | -83.61M | -99.32M | -569k |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 226.49M | 260.89M | 234.63M | 209.19M | 221.17M |
| Total Liabilities | 198.02M | 346.64M | 321.27M | 294.21M | 272.41M |
| Total Equity | 28.47M | -85.75M | -86.64M | -85.03M | -51.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 341.28M | 358.66M | 339.41M | 260.89M | 201.79M |
| Total Liabilities | 290.17M | 308.86M | 250.03M | 346.64M | 249.24M |
| Total Equity | 51.11M | 49.8M | 89.38M | -85.75M | -47.45M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -109.39M | -110.79M | 9.35M | -15.83M | -34.07M |
| Investing | -1.56M | 98.26M | -146.64M | -120.6M | -163.54M |
| Financing | 458k | 648k | N/A | 317k | 29.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -140.48M | 5.26M | -119.03M | -110.79M | -56.04M |
| Investing | 79.7M | -18.72M | 22.49M | 98.26M | -150.67M |
| Financing | 1.63M | 16.89M | 110.21M | 648k | 30.23M |
| Market Cap | 117.16M |
| Price to Earnings Ratio | -205.95 |
| Price to Sales Ratio | 1.16 |
| Price to Cash Ratio | 6.82 |
| Price to Book Ratio | -2.47 |
| Dividend Yield | - |
| Shares Outstanding | 67.72M |
| Average Volume (1 week) | 485.21k |
| Average Volume (1 Month) | 676.07k |
| 52 Week Change | 4.85% |
| 52 Week High | 2.855 |
| 52 Week Low | 1.04 |
| Spread (Intraday) | 0.29 (14.43%) |
| Company Name | CytomX Therapeutics Inc |
| Address |
850 new burton road dover, delaware 19904 |
| Website | https://www.cytomx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
